Brookline Capital Markets Downgrades Adial Pharmaceuticals (NASDAQ:ADIL) to Hold

Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) was downgraded by Brookline Capital Markets from a “strong-buy” rating to a “hold” rating in a research report issued on Thursday,Zacks.com reports.

Several other equities research analysts have also recently issued reports on ADIL. Weiss Ratings reissued a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research note on Monday, April 20th. UBS Group set a $8.00 target price on Adial Pharmaceuticals in a research note on Wednesday, February 11th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Adial Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $22.75.

Get Adial Pharmaceuticals alerts:

Read Our Latest Stock Report on Adial Pharmaceuticals

Adial Pharmaceuticals Price Performance

NASDAQ ADIL opened at $2.98 on Thursday. The company has a market cap of $6.38 million, a PE ratio of -0.37 and a beta of 1.46. The stock’s 50 day simple moving average is $1.86 and its 200-day simple moving average is $3.63. Adial Pharmaceuticals has a 1-year low of $1.31 and a 1-year high of $18.90.

Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) last posted its quarterly earnings results on Friday, May 8th. The company reported ($1.48) EPS for the quarter, beating the consensus estimate of ($2.73) by $1.25. On average, equities research analysts anticipate that Adial Pharmaceuticals will post -7.09 EPS for the current fiscal year.

Institutional Trading of Adial Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ADIL. Jane Street Group LLC lifted its holdings in shares of Adial Pharmaceuticals by 887.3% in the 4th quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock valued at $27,000 after purchasing an additional 109,500 shares during the last quarter. Citadel Advisors LLC acquired a new position in Adial Pharmaceuticals in the 3rd quarter valued at about $51,000. Finally, Armistice Capital LLC acquired a new position in Adial Pharmaceuticals in the 4th quarter valued at about $562,000. 16.41% of the stock is owned by hedge funds and other institutional investors.

Adial Pharmaceuticals Company Profile

(Get Free Report)

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.

Read More

• Five stocks we like better than Adial Pharmaceuticals
• SpaceX Rings the Bell and Shatters Every Record
• Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
• 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
• The 127-Gigawatt Problem: Why AI Needs Its Own Power

Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.